PERIOZIP for feline periodontal disease management
PERIOZIP is an innovative smart polymeric gel designed to manage feline periodontitis by delivering active biomaterials locally. It offers benefits like biodegradability, selective pathogen targeting, and reduced need for surgery, while ensuring no resistance development.
Overview
PERIOZIP represents a groundbreaking solution for managing periodontal disease in cats. This smart polymeric gel is prefilled in a syringe and targets periodontitis by delivering active biomaterials directly to affected areas. Upon application into the periodontal pocket, the gel hardens and releases therapeutic agents over a 7-14 day period. This approach not only addresses tooth loss and pain but also minimizes the use of antibiotics and surgical interventions. The gel’s ability to selectively eliminate pathogens without harming beneficial bacteria makes it a standout solution in veterinary medicine.
Technical specifications
Key features:
- Local delivery: Delivers active, natural substances directly to diseased areas.
- Biodegradable and biocompatible: Ensures no adverse effects on host tissue.
- Selective antimicrobial action: Targets pathogens while preserving beneficial commensals, reducing the risk of resistance.
- Prolonged treatment capability: Suitable for repeated applications with no side effects.
- Multifunctional: Reduces the need for invasive dental procedures through controlled and efficient drug delivery.
Technology readiness level
PERIOZIP has achieved a Technology Readiness Level (TRL) of 6, indicating that it has been demonstrated in a relevant environment. Future plans include efficacy studies, safety assessments, formulation optimizations, and ensuring regulatory compliance to further validate its use in veterinary practice.
About RamaZottius Lab
RamaZottius Lab is a Lithuanian medtech startup specializing in the development of innovative solutions for periodontal disease. The company's flagship product, Periozip, is a specialized gel featuring an advanced smart biomaterial of natural plant origin. Designed for application via a prefilled syringe directly into periodontal pockets, the product aims to harden within the cavity to inhibit the viability of disease-causing microorganisms. By providing a non-invasive alternative to traditional surgical interventions, the technology seeks to facilitate the repair of periodontal tissues while reducing the need for antibiotics and associated surgical risks.
Since its founding in 2020, the company has combined pharmaceutical biotechnology expertise with entrepreneurial leadership to address clinical needs in dental health. Supported by various European health innovation grants and clinical trials, the company is focused on securing CE certification for Periozip as a Class IIa medical device and scaling its commercialization through licensing and strategic partnerships. RamaZottius Lab aims to improve patient outcomes by offering safer, non-invasive treatment options that protect gums and prevent tooth loss, positioning itself within the deep-tech ecosystem to expand its international reach.
Inquire about this partnering listing
Industry applications
delivered to your inbox.